Linagliptin

Ingoa matū:

8-[(3R)-3-aminopiperidin-1-yl]-7-(engari-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dione

Waehere SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Waehere InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

Kī InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Kupumatua:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Wairewa:Wairewa i roto i te DMSO

Rokiroki:0 - 4°C mo te wa poto (ra ki nga wiki), -20°C ranei mo te wa roa (marama).

Whakaahuatanga:

Ko Linagliptin, e mohiotia ana ko BI-1356, he aukati DPP-4 i hangaia e Boehringer Ingelheim mo te maimoatanga o te mate huka momo II. Ko te Linagliptin (kotahi ia ra) i whakaaetia e te US FDA i te 2 o Mei 2011 mo te maimoatanga o te mate huka momo II. Kei te hokohoko a Boehringer Ingelheim me Lilly.

Whāinga: DPP-4